Precision Biosciences (DTIL) Change in Accured Expenses (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Change in Accured Expenses data on file, last reported at -$1.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 64.91% year-over-year to -$1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 210.72% YoY) and the FY2025 annual result came in at -$1.8 million, up 17.2% from the prior year.
• Change in Accured Expenses slipped to -$1.8 million in Q1 2026 per DTIL's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.4 million in Q2 2022 and bottomed at -$5.8 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $474000.0 (2022), against an average of -$483882.4.
• The widest annual swing landed in 2022, when Change in Accured Expenses plunged 139.98%; it then jumped 1478.85% in 2025.
• Tracing DTIL's Change in Accured Expenses over 5 years: stood at $421000.0 in 2022, then soared by 464.61% to $2.4 million in 2023, then sank by 106.56% to -$156000.0 in 2024, then jumped by 1478.85% to $2.2 million in 2025, then tumbled by 183.5% to -$1.8 million in 2026.
• Per Business Quant, the three latest DTIL Change in Accured Expenses figures stand at -$1.8 million (Q1 2026), $2.2 million (Q4 2025), and $528000.0 (Q3 2025).

Peer Comparison